BANK VONTOBEL/PUT/BIONTECH ADR/94/0.1/20.09.24 Share Price

Warrant

PX45V

DE000VM7W2J9

Real-time Euronext Paris 11:36:11 27/06/2024 am IST
1.175 EUR +2.62% Intraday chart for BANK VONTOBEL/PUT/BIONTECH ADR/94/0.1/20.09.24
Current month+136.08%
1 month+92.44%
Date Price Change
27/24/27 1.175 +2.62%
26/24/26 1.145 +12.81%
25/24/25 1.015 +8.56%
24/24/24 0.935 -13.02%
21/24/21 1.075 +8.04%

Real-time Euronext Paris

Last update June 27, 2024 at 11:36 am IST

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying BIONTECH SE
IssuerLogo Issuer Vontobel Vontobel
PX45V
ISINDE000VM7W2J9
Date issued 08/01/2024
Strike 94 $
Maturity 20/09/2024 (86 Days)
Parity 10 : 1
Emission price 0.68
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1.275
Lowest since issue 0.385
Delta-0.74x
Omega 4.998
Premium0.93x
Gearing6.74x
Moneyness 1.139
Difference Strike 11.48 $
Difference Strike %+12.21%
Spread 0.01
Spread %0.87%
Theoretical value 1.175
Implied Volatility 35.94 %
Total Loss Probability 22.17 %
Intrinsic value 1.074
Present value 0.1014
Break even 81.44 €
Theta-0.01x
Vega0.01x
Rho-0.01x

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
More about the company

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: BioNTech SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
77.26 EUR
Average target price
103.5 EUR
Spread / Average Target
+33.99%
Consensus
  1. Stock Market
  2. Warrants
  3. PX45V Warrant